BrainLife | Library
CNS Tumors
Familial tumor syndromes
Neurofibromatosis type 1


Home > Library > CNS Tumors > Familial tumor syndromes > Neurofibromatosis type 1



Contents



CASE REPORTS


CLASSIFICATION


DIAGNOSIS, PRESENTATION


EPIDEMIOLOGY, RISK FACTORS


ETIOLOGY, PATHOGENESIS, PATHOLOGY


FOLLOW-UP, SIDE EFFECTS, QUALITY OF LIFE


INTEGRATIVE MEDICINE


OVERALL MANAGEMENT


PROGNOSIS, OUTCOMES


TREATMENT



Case reports



Campen CJ, Gutmann DH.
Optic Pathway Gliomas in Neurofibromatosis Type 1.
J Child Neurol. [2017 Dec 15]. 2018;33(1):73-81. Doi 10.1177/0883073817739509. _




Flower H, Gallo P.
Cerebellar glioblastoma in an NF1 patient. Is it surgical debulking really necessary?
Br J Neurosurg. [2019 Nov 20]. 2019;1-3. Doi 10.1080/02688697.2019.1690127. _




Kinori M, Armarnik S, Listernick R, Charrow J, Zeid JL.
Neurofibromatosis type 1 associated optic pathway glioma in children - a follow up of 10 years or more.
Am J Ophthalmol. [2020 Apr 10]. 2020;S0002-9394(20)30165-3. Doi 10.1016/j.ajo.2020.03.053. _




Spyris CD, Castellino RC, Schniederjan MJ, Kadom N.
High-Grade Gliomas in Children with Neurofibromatosis Type 1: Literature Review and Illustrative Cases.
AJNR Am J Neuroradiol. [2018 Dec 20]. 2019;40(2):366-369. Doi 10.3174/ajnr.A5888. _



Etiology, Pathogenesis, Pathology



D'Angelo F, Ceccarelli M, Tala, Garofano L, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras CE, McCutcheon I, Nam DH, Ronchi S, Saletti V, Seizeur R, Slopis J, Suñol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss DE, Kim SK, Meyronet D, Mokhtari K, Salvador H, Bhat KP, Eoli M, Sanson M, Lasorella A, Iavarone A.
The molecular landscape of glioma in patients with Neurofibromatosis 1.
Nat Med. [2018 Dec 10]. 2019;25(1):176-187. Doi 10.1038/s41591-018-0263-8. _



Overall management



Cassina M, Frizziero L, Opocher E, Parrozzani R, Sorrentino U, Viscardi E, Miglionico G, Midena E, Clementi M, Trevisson E.
Optic Pathway Glioma in Type 1 Neurofibromatosis: Review of Its Pathogenesis, Diagnostic Assessment, and Treatment Recommendations.
Cancers (Basel). 2019 Nov 14. 2019;11(11). Doi 10.3390/cancers11111790. _




Lobbous M, Bernstock JD, Coffee E, Friedman GK, Metrock LK, Chagoya G, Elsayed G, Nakano I, Hackney JR, Korf BR, Nabors LB.
An Update on Neurofibromatosis Type 1-Associated Gliomas.
Cancers (Basel). 2020 Jan 1. 2020;12(1):E114. Doi 10.3390/cancers12010114. _




Plotkin SR, Wick A.
Neurofibromatosis and Schwannomatosis.
Semin Neurol. [2018 Mar 16]. 2018;38(1):73-85. Doi 10.1055/s-0038-1627471. _



GUIDELINES



Bergqvist C, Servy A, Valeyrie-Allanore L, Ferkal S, Combemale P, Wolkenstein P; NF France Network.
Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.
Orphanet J Rare Dis. 2020 Feb 3. 2020;15(1):37. Doi 10.1186/s13023-020-1310-3. _



Treatment




Overview


Review

Brosseau JP, Liao CP, Le LQ.
Translating current basic research into future therapies for neurofibromatosis type 1.
Br J Cancer. [2020 May 22]. 2020;10.1038/s41416-020-0903-x. Doi 10.1038/s41416-020-0903-x. _



Review

Karaconji T, Whist E, Jamieson RV, Flaherty MP, Grigg JRB.
Neurofibromatosis Type 1: Review and Update on Emerging Therapies.
Asia Pac J Ophthalmol (Phila). [2018 Nov 2]. 2019;8(1):62-72. Doi 10.22608/APO.2018182. _



Clinical investigations



Ullrich NJ, Prabhu SP, Reddy AT, Fisher MJ, Packer R, Goldman S, Robison NJ, Gutmann DH, Viskochil DH, Allen JC, Korf B, Cantor A, Cutter G, Thomas C, Perentesis JP, Mizuno T, Vinks AA, Manley PE, Chi SN, Kieran MW; NF Clinical Trials Consortium.
A Phase II Study of Continuous Oral mTOR Inhibitor Everolimus for Recurrent, Radiographic-Progressive Neurofibromatosis Type 1-Associated Pediatric Low-Grade Glioma: A Neurofibromatosis Clinical Trials Consortium Study.
Neuro Oncol. [2020 Apr 1]. 2020;noaa071. Doi 10.1093/neuonc/noaa071. _